Literature DB >> 20146692

The tuberous sclerosis complex.

Ksenia A Orlova1, Peter B Crino.   

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder that results from mutations in the TSC1 or TSC2 genes and is associated with hamartoma formation in multiple organ systems. The neurological manifestations of TSC are particularly challenging and include infantile spasms, intractable epilepsy, cognitive disabilities, and autism. Progress over the past 15 years has demonstrated that the TSC1 or TSC2 encoded proteins modulate cell function via the mTOR signaling cascade and serve as keystones in regulating cell growth and proliferation. The mTOR pathway provides an intersection for an intricate network of protein cascades that respond to cellular nutrition, energy levels, and growth-factor stimulation. In the brain, TSC1 and TSC2 have been implicated in cell body size, dendritic arborization, axonal outgrowth and targeting, neuronal migration, cortical lamination, and spine formation. Antagonism of the mTOR pathway with rapamycin and related compounds may provide new therapeutic options for TSC patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20146692      PMCID: PMC2892799          DOI: 10.1111/j.1749-6632.2009.05117.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  159 in total

1.  Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner.

Authors:  Ariel F Castro; John F Rebhun; Geoffrey J Clark; Lawrence A Quilliam
Journal:  J Biol Chem       Date:  2003-07-03       Impact factor: 5.157

Review 2.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

3.  The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho.

Authors:  R F Lamb; C Roy; T J Diefenbach; H V Vinters; M W Johnson; D G Jay; A Hall
Journal:  Nat Cell Biol       Date:  2000-05       Impact factor: 28.824

4.  Embryonic neuronal markers in tuberous sclerosis: single-cell molecular pathology.

Authors:  P B Crino; J Q Trojanowski; M A Dichter; J Eberwine
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

5.  Allelic loss at the tuberous sclerosis 2 locus in spontaneous tumors in the Eker rat.

Authors:  R S Yeung; G H Xiao; J I Everitt; F Jin; C L Walker
Journal:  Mol Carcinog       Date:  1995-09       Impact factor: 4.784

6.  A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer.

Authors:  T Kobayashi; Y Hirayama; E Kobayashi; Y Kubo; O Hino
Journal:  Nat Genet       Date:  1995-01       Impact factor: 38.330

7.  Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin.

Authors:  Nisreen El-Hashemite; Victoria Walker; Hongbing Zhang; David J Kwiatkowski
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

8.  A cross sectional study of renal involvement in tuberous sclerosis.

Authors:  J A Cook; K Oliver; R F Mueller; J Sampson
Journal:  J Med Genet       Date:  1996-06       Impact factor: 6.318

9.  TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

Authors:  James B Brugarolas; Francisca Vazquez; Archana Reddy; William R Sellers; William G Kaelin
Journal:  Cancer Cell       Date:  2003-08       Impact factor: 31.743

10.  Germ-line Tsc2 mutation in a dominantly inherited cancer model defines a novel family of rat intracisternal-A particle elements.

Authors:  G H Xiao; F Jin; R S Yeung
Journal:  Oncogene       Date:  1995-07-06       Impact factor: 9.867

View more
  161 in total

1.  Inhibition of glycogen synthase kinase 3[beta] activity with lithium in vitro attenuates sepsis-induced changes in muscle protein turnover.

Authors:  Stephen Bertsch; Charles H Lang; Thomas C Vary
Journal:  Shock       Date:  2011-03       Impact factor: 3.454

2.  Tuber-Less Models of Tuberous Sclerosis Still Provide Insights Into Epilepsy.

Authors:  Michael Wong
Journal:  Epilepsy Curr       Date:  2015 May-Jun       Impact factor: 7.500

3.  More Than mTOR? Novel Roles for MEK-ERK1/2 and FLNA in Tuberous Sclerosis Complex.

Authors:  Chris G Dulla
Journal:  Epilepsy Curr       Date:  2015 Jul-Aug       Impact factor: 7.500

Review 4.  Epilepsy: A Spectrum Disorder.

Authors:  Joseph I Sirven
Journal:  Cold Spring Harb Perspect Med       Date:  2015-09-01       Impact factor: 6.915

5.  Association between the growth rate of renal cysts/angiomyolipomas and age in the patients with tuberous sclerosis complex.

Authors:  Jeng-Dau Tsai; Chang-Ching Wei; Shan-Ming Chen; Ko-Huang Lue; Ji-Nan Sheu
Journal:  Int Urol Nephrol       Date:  2014-03-30       Impact factor: 2.370

6.  Role of vascular and lymphatic endothelial cells in hantavirus pulmonary syndrome suggests targeted therapeutic approaches.

Authors:  Erich R Mackow; Elena E Gorbunova; Nadine A Dalrymple; Irina N Gavrilovskaya
Journal:  Lymphat Res Biol       Date:  2013-09-11       Impact factor: 2.589

7.  The mTOR pathway in treatment of epilepsy: a clinical update.

Authors:  Jennifer L Griffith; Michael Wong
Journal:  Future Neurol       Date:  2018-05-29

Review 8.  Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies.

Authors:  Trent R Hummel; Lionel M Chow; Maryam Fouladi; David Franz
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

9.  The specificity and role of microglia in epileptogenesis in mouse models of tuberous sclerosis complex.

Authors:  Bo Zhang; Jia Zou; Lirong Han; Brennan Beeler; Joseph L Friedman; Elizabeth Griffin; Yue-Shan Piao; Nicholas R Rensing; Michael Wong
Journal:  Epilepsia       Date:  2018-08-05       Impact factor: 5.864

Review 10.  Genetic animal models of malformations of cortical development and epilepsy.

Authors:  Michael Wong; Steven N Roper
Journal:  J Neurosci Methods       Date:  2015-04-21       Impact factor: 2.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.